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Abstract
Despite the introduction of new and more expensive anticonvulsant drugs, 
phenytoin (PHT) is still a first-line medication for common types of epilepsy such 
as tonic-clonic and complex partial seizures but not for absence seizures. PHT 
shows a nonlinear kinetics and a narrow therapeutic range, thus a fine balance 
must be found between efficacy and toxic effects. Since the free (unbound) drug is 
responsible for producing the pharmacological effect, the concentration in a novel 
biological fluid more closely related to arterial free plasma drug concentration—
saliva—is used in this study as part of the monitoring strategy. Therefore, in order 
to optimize therapy in epileptic patients under PHT treatment, plasma and saliva 
concentrations of PHT were measured, and adverse drug reactions were registered 
during a 2-year follow-up. CYP2C9, CYP2C19, and epoxide hydrolase polymor-
phisms (enzymes involved in PHT metabolism) were also analyzed using, in this 
way, pharmacogenetics for drug safety. The two PHT brands commercially available 
in our country and used in this study demonstrated similar pattern of efficacy and 
safety.
Keywords: phenytoin, pharmacovigilance, therapeutic drug monitoring, 
pharmacokinetics, pharmacogenetics
1. Introduction
Phenytoin (PHT) is approved to be used for almost any type of epilepsy such 
as generalized tonic-clonic and complex partial (psychomotor and temporal lobe) 
seizures and for preventing and treating seizures occurring during or following 
neurosurgery except for absence seizures [1]. Regarding its mechanism of action, 
PHT exerts a stabilizing effect on excitable membranes of several cells, including 
neurons and cardiac myocytes. It inhibits voltage-dependent sodium channels, 
reducing sodium flow during action potential [2]. Taking into account, PHT has 
a narrow therapeutic range; therapies with this drug are monitored by plasma 
quantification in the routine practice [3]. However, when using plasma drug 
concentrations in therapeutic drug monitoring (TDM), free plus protein bound 
drug is measured. As it is known, plasma or serum concentration does not usually 
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represent the concentration at its receptor site. Only free drug can reach the bio-
phase (action site) and interact with a receptor to produce the effect (therapeutic 
or toxic). Total drug concentrations depend on protein binding, and PHT is highly 
bound to albumin. But, free drug monitoring is rather expensive for routine 
practice. Our research group has been working for several years using saliva as 
biological fluid [4–6]. Saliva is not only useful for being a simple and noninvasive 
collection method but also for the information it gives. Studies have demonstrated 
that salivary concentrations highly correlate with free drug concentration in plasma 
mainly for drugs, which are lipophilic and nonionized at salivary pH (i.e., phe-
nytoin or carbamazepine), and therefore, saliva concentrations are more reflective 
of the concentration at the biophase. Saliva is produced in the salivary glands by 
ultrafiltration of arterial plasma. Arterial drug concentration is higher than the 
respective venous concentration during drug input either after intravenous or oral 
administration [7]. So if enterohepatic or blood-gastrointestinal cycling processes 
are operating, elevated saliva drug concentrations (reflecting higher arterial drug 
concentrations) during the elimination phase could predict re-entry processes. 
Using this fluid, our research group has studied enterohepatic recirculation of 
paracetamol [8] and blood gastrointestinal cycling of methadone [9].
It is important to note that for the treatment of epilepsy, the effective and safe 
plasma concentrations referenced in the literature are between 10 and 20 mg/L, 
and salivary concentrations are between 1 and 2 mg/L. The narrow population 
therapeutic range, the clinical consequences of presenting subtherapeutic or toxic 
concentrations, and the difficulty of determining the pharmacokinetic parameters 
for each patient predispose the clinician to follow the therapy with this anticonvul-
sant agent through a frequent determination of plasma and/or salivary concentra-
tions in each patient. Therefore, the dose range compatible with a therapeutic serum 
or a saliva concentration is narrow within subjects, and TDM is of particular value 
in dosage tailoring [3, 10].
PHT is a weak acid, which usually administered as the sodium salt. Its solubility 
in water is scarce even in the intestine as it precipitates at the intestinal pH, a fact 
that conditions its entry into the body. However, it is well absorbed when adminis-
tered orally, with a bioavailability close to 90%, which implies that in addition to the 
great lipophilicity that it presents, the metabolism at the enterocyte level is low. The 
drug has a volume of distribution of 0.64 L/kg and is approximately 90% bound 
to plasma proteins [10, 11]. PHT main biotransformation route is para-hydrox-
ylation to form the inactive metabolite 5-(4-hydroxyphenyl)-5-phenylhydantoin 
(p-HPPH). The enzyme involved in this step is CYP2C9 and, to a lesser extent, 
CYP2C19 [11]. p-HPPH formation occurs via an arene-oxide intermediate, and the 
accumulation of the latter can be the cause of skin reactions associated with PHT 
[12, 13]. Further oxidation of p-HPPH leads to catechol formation (3′-4’-diHPPH), 
by CYP2C9, CYP2C19, and CYP3A4, also undergoing an arene-oxide intermediate. 
On the other side, the arene oxide can also be converted to transdihydrodiol phe-
nytoin via microsomal epoxide hydrolase (EPXH), which can also lead to catechol 
formation. The enzymes CYP2C9, CYP2C19, and EPHX are polymorphically 
expressed [14–16].
There is strong evidence that PHT undergoes an important secretion from 
blood to the digestive tract after which the drug would re-enter the body from the 
intestinal lumen. Observations of secondary peaks in plasma concentration profiles 
after intravenous doses of PHT constitute strong arguments to affirm the important 
contribution of recirculation between internal medium and gastrointestinal lumen 
in the pharmacokinetics of this drug [17–19].
PHT was traditionally believed to saturate the hepatic enzymes and there-
after giving rise to a nonlinear concentration-dose relationship, described by 
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the Michaelis-Menten equation. An alternative hypothesis based on its ability to 
induce efflux transporters was reported by our group, and this inductive effect was 
demonstrated in rats to be time-and-concentration-dependent [20–22]. The efflux 
transporter involved would be MRP2, and by means of this efflux pump, the drug 
would be secreted, in an important way, towards the digestive tract, thus propitiat-
ing the appearance of secondary peaks even after its intravenous administration. 
The induction of its expression would slow the oral absorption of PHT, a fact that 
is noticeable when analyzing the plasma profiles of the drug during the interval 
of administration in multiple doses, which are much less acute than the profiles 
observed after single doses. On the other hand, the deviation of the drug from the 
liver to the intestine would avoid the major biotransformation that takes place in the 
hepatocyte. Given the greater abundance of CYP2C9 and CYP2C19 enzymes pres-
ent in the liver in relation to the enterocytes, a reduction in clearance in a concen-
tration-dependent manner as verified during chronic treatments could be observed. 
In other words, the nonlinear kinetics found for this drug would not correspond to 
an enzymatic saturation but to an induction in the expression of transporters that 
remove molecules from the sites of high metabolism [20, 22].
The toxic effects of PHT depend on the route of administration, the duration 
of exposure, and the dose [23]. When administered IV with an excessive speed 
for status epilepticus, the most important toxic signs are cardiac arrhythmias with 
or without hypotension and central nervous system depression. These complica-
tions are reduced with the slow administration of diluted solutions of the drug. IV 
administration of PHT should not exceed 50 mg/minute for adults and should be 
well diluted in physiological solution in order to reduce local venous irritation due 
to the alkalinity of drug solutions [24–26].
The toxic effects associated with chronic treatment include concentration-
related effects, as well as confusion, behavioral disturbances, increased frequency 
of seizures, gastrointestinal symptoms, hirsutism, gingival hyperplasia, osteo-
malacia, and megaloblastic anemia. Undesirable effects include vertigo, ataxia, 
headache, diplopia, and nystagmus but not sedation. Increased incidence of fetal 
malformations (mainly cleft palate) has been observed in children born from epi-
leptic mothers under PHT treatment. Occasionally, increased hepatic transaminases 
are also observed [27].
The reported endocrine effects are diverse. Osteomalacia with hypocalcemia and 
increased alkaline phosphatase has been attributed both to an increased vitamin D 
metabolism due to the inducing effect of PHT and to inhibition of intestinal cal-
cium absorption. PHT also increases the metabolism of vitamin K and reduces the 
concentration of vitamin K-dependent proteins that are important for the normal 
metabolism of calcium in bone [28].
Hypersensitivity reactions can vary from mild rashes in 2–5% of patients to 
sometimes more severe and life-threatening skin reactions such as Stevens-Johnson 
syndrome [29].
Active pharmacovigilance, in contrast to passive, seeks to ascertain the number 
of adverse reactions (lack of efficacy or toxicity) via a continuous process. An 
example of active surveillance is the follow-up of patients treated with a particu-
lar drug. In general, it is more feasible to get more comprehensive data from the 
particular drug behavior through an active pharmacovigilance system than through 
a passive reporting system.
Nowadays, two commercial brands of PHT are available in Uruguay for oral 
administration, both multisource drug products (Antepil® and Comitoína®). Due 
to the characteristics of PHT previously mentioned, there is a need to evaluate 
these products in their natural clinical setting because the clinical response is never 
assessed in bioequivalence studies carried out with healthy volunteers.
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2. Objective
The objective of this study was to optimize PHT therapeutics by active phar-
macovigilance in epileptic patients under PHT treatment (either Antepil® or 
Comitoína®) measuring plasma and saliva concentrations, determining CYP2C9, 
CYP2C19, and epoxide hydrolase (EPHX) polymorphisms, registering adverse drug 
reactions (ADR) during a 2-year time period, and demonstrating that both PHT 
brands have similar pattern of efficacy and safety.
3. Patients and methods
3.1 Subjects and design
The inclusion criteria for patients included a diagnosis of epilepsy carried out 
by the attending neurologist. Some patients were treated only with Antepil® for 
the study period of 2 years, and some were treated only with Comitoína® during 
the same period. Patients with hepatic or renal impairment, pregnant and lactating 
women, and individuals with history of alcohol or drug abuse or addiction or with 
diminished intellectual or motor abilities were excluded from the study. The study 
protocol was approved by the Institutional Ethics Review Committee of the Faculty 
of Chemistry, Universidad de la República, and written consent was obtained from 
all subjects prior to their participation in the study.
All the information about PHT concentrations in plasma and saliva, PHT 
dose and dosing interval, comedications, adverse effects (lack of efficacy or toxic 
effects), and laboratories results (liver and renal function and hemogram tests, 
albumin in blood) of the patients were collected by the pharmacists of the program 
using a data sheet elaborated for this purpose every time the patient came for the 
interview and for blood and saliva analysis (see Section 3.2).
One electroencephalogram in the 2-year period was also obtained.
Patients also had a form in which they wrote down any ADR they experienced, 
indicating start time and duration. Patients called the neurologists of the phar-
macovigilance program when an ADR occurred and the physician determined 
the action to take and communicated this action to the pharmacists. All the ADRs 
were notified to the Pharmacovigilance Unit of the Health Ministry completing the 
Yellow Form. The causality assessment of ADRs was carried out using Naranjo’s 
algorithm as shown in Table 1.
3.2 Sampling and chemical analysis
The pharmacovigilance protocol includes predose blood and saliva samples 
every 3 months and salivary curves when the subject was included in the study and 
1 year later. Laboratory tests were performed twice in the 2-year period except for 
albumin in blood that was carried out in every occasion.
Predose blood samples (5 mL) were taken from the antecubital vein and placed 
into heparinized tubes, and saliva samples were obtained by stimulation with citric 
acid and scheduled before dose intake and at 1, 2, 3, 4, 5, 6, 8, and 12 hours after 
dosing. Blood and saliva samples were centrifuged and stored in freezer (−25°C) 
until analysis.
Quantification of PHT in saliva was carried out by Chemiluminescent 
Microparticle Immunoassay (CMIA), using Architect (Abbot™) equipment, accord-
ing to the instructions given in the package insert. Precision and accuracy were below 
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15% and between 85 and 115%, respectively, except at the lower limit of quantifica-
tion (0.3 mg/L), where intra- and inter-day coefficient of variation rose up to 20%.
Plasma PHT and p-HPHH concentrations were determined by a high perfor-
mance liquid chromatography (HPLC) method based on a procedure previously 
published by Savio et al. [30]. The method was linear between 0.5286 mg/L (the 
lower limit of quantification, LLOQ ) and 24.39 mg/L for PHT and between 
0.0585 mg/L (LLOQ ) and 2.701 mg/L for p-HPPH.
3.3 Pharmacokinetic and statistical analysis
The following pharmacokinetic parameters at steady state (ss) were determined 
from the experimental salivary PHT concentration curves versus time:
• Area under the saliva PHT concentration-time curve from 0 to 𝑇 hours (AUCss 
0–𝑇) calculated by the linear trapezoidal rule with 𝑇 being the administration 
interval.
• Experimental maximum and minimum concentration (𝐶maxss and 𝐶minss) of 
the curve.
• Time to obtain maximum concentration (𝑇maxss).
• Mean concentration (𝐶meanss = AUCss 0–𝑇/𝑇).
• Peak-to-trough fluctuation [PTF = (𝐶maxss − 𝐶minss) × 100/𝐶meanss].
Question Yes No Do not 
know
Score
1. Are there previous conclusive reports on this reaction? +1 0 0
2. Did the adverse event appear after the suspected drug was          
administered?
+2 −1 0
3. Did the adverse event improve when the drug was discontinued 
or a specific antagonist was administered?
+1 0 0
4. Did the adverse event reappear when the drug was 
readministered?
+2 −1 0
5. Are there alternative causes that could on their own have 
caused the reaction?
−1 +2 0
6. Did the reaction reappear when a placebo was given? −1 +1 0
7. Was the drug detected in blood or other fluids in 
concentrations known to be toxic?
+1 0 0
8. Was the reaction more severe when the dose was increased or 
less severe when the dose was decreased?
+1 0 0
9. Did the patient have a similar reaction to the same or similar 
drugs in any previous exposure?
+1 0 0
10. Was the adverse event confirmed by any objective evidence? +1 0 0
Total score:
Total score: >9 = definitive reaction, 5–8 = probable, 1–4 = possible, ≤0 = doubtful.
Table 1. 
Naranjo’s casuality algorithm.
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The statistical processing of the information was carried out using the statistical 
program Statistical Package for the Social Sciences, version 17 (SPSS), and it was 
by obtaining mean values, standard deviations, and 95% confidence intervals (95% 
CI) of the pharmacokinetic parameters.
3.4 Genotyping procedure of EPHX, CYP2C9, and CYP2C19
Genotyping procedure of EPHX, CYP2C9, and CYP2C19 was carried out by 
Genia (Molecular Genetics Laboratory, Montevideo, Uruguay). EPHX polymor-
phism was done by real-time polymerase chain reaction (RT-PCR). To determine 
CYP2C9 and 2C19 genotype, a conventional PCR was performed for each SNP (rs 
1799853 and rs 1057910 for CYP2C9; rs 4244285 and rs 4986893 for CYP2C19). The 
complete technique is specified in the study performed by our group [31].
3.5 In vitro dissolution study
Six units of each product were tested in Distek® Dissolution System 2100C 
equipment. The conditions were as follows: USP 32 Apparatus 2 (paddle); 75 rpm 
stirring speed; volume 900 mL of water; and temperature 37 ± 0.5°C. Samples were 
automatically withdrawn by the use of an Agilent 89092EO pump at 10, 15, 20, 30, 
40, 60, and 80 minutes. The drug release at different time intervals was measured 
by UV-visible spectrophotometer (Agilent 8453 and ChemStation® software).
4. Results and discussion
A total of 57 adult Caucasian epileptic subjects were included in the active 
pharmacovigilance program. Thirty-three individuals were receiving a conventional 
dose of Antepil® 100 mg (Fármaco Uruguayo Laboratory) and 24 of Comitoína® 
100 mg (Roemmers Laboratory). The demographic characteristics of the subjects 
for Antepil® and Comitoína® are summarized in Tables 2 and 3, respectively.
The in vitro dissolution assay demonstrated a slow release drug rate for both 
brands as it can be seen in Figure 1 but with a faster onset for Antepil®. This is in 
accordance with the saliva concentration-time profiles of both brands as shown in 
Figures 2 and 3. Although the saliva profiles are similar, a delay at the beginning of 
the absorption can be seen in Comitoína® profile (Figure 3).
Several secondary peaks can be observed after diurnal administration of PHT 
(Figures 2 and 3), and this is evidencing the PHT recirculation processes that have 
already been studied by our group and other researchers as it was stated in Section 
1. PHT could be stored in the digestive system organs to be later excreted to the 
small intestine lumen, from where it can re-enter into the bloodstream. This phe-
nomenon would be favored by the overexpression of efflux transporters at the bile 
canaliculus caused by PHT, which would accelerate the escape of PHT molecules 
from hepatocyte that is the main site of drug metabolism by CYP2C9 and CYP2C19, 
Total Male Female
Subjects 33 15 18
Age (years) 46.6 (18–75) 42.0 (18–73) 50.4 (20–75)
Weight (kg) 75.8 (45–140) 75.9 (49–140) 75.7 (45–120)
Table 2. 
Demographic characteristics of the patients under Antepil® treatment expressed as mean (95% CI).
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deviating it to the intestinal lumen where metabolizing enzyme expression is poor, 
an adverse from where it would be available to re-entry into the bloodstream. As it 
can be observed in both figures, there is no important PTF.
Mean plasma protein binding of PHT was 89% for Antepil® and 90% for 
Comitoína®, which do not differ from the literature (80–90%). The plasma protein 
binding (PPB) was obtained as follows:
  PPB = 100 x   (1 −  [So] / [Po] ) . (1)
Being So and Po predose saliva and plasma concentration, respectively.
Total Male Female
Subjects 24 12 12
Age (years) 45.8 (18–76) 47.8 (25–76) 44.0 (18–69)
Weight (kg) 76.5 (48–108) 80.1 (54–100) 66.9 (48–108)
Table 3. 
Demographic characteristics of the patients under Comitoína® treatment expressed as mean (95% CI).
Figure 1. 
Dissolution profile of the two brands of phenytoin in water.
Figure 2. 
Mean (±standard error) saliva PHT concentration-time profile after the administration of Antepil®.
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Figure 3. 
Mean (±standard error) saliva PHT concentration-time profile after the administration of Comitoína®.
Serum albumin levels were between the reference range (3.30–5.00 g/dL) in all 
the subjects and in every occasion. No laboratories abnormalities were observed for 
any subject or brand during the 2-year study, except for ammonia levels determined 
only in some patients comedicated with valproic acid (VPA).
No significant differences were found in the normalized doses or in the salivary 
and plasma concentrations between men and women for either brand. However, 
there is a tendency for women to have lower plasma and saliva PHT concentration 
for equal normalized doses. Further studies with a greater number of individuals 
are needed to confirm this tendency. The explanation could be a greater apparent 
clearance in women due to either a higher systemic clearance of the drug or a lower 
oral bioavailability. Both could be probably given the greater expression of MRP2 
and the higher fraction of cardiac output delivered to the intestine that women 
present in comparison to men.
Figures 4 and 5 show both plasma and salivary drug concentrations in response 
to the administered daily doses for Comitoína® and Antepil®, respectively.
Both Figures 4 and 5 show the typical curvature of Michaelis-Menten kinetics 
described in the literature for plasma concentrations, considering a limited enzyme 
capacity. However, as explained in Section 1, an alternative hypothesis could explain 
the nonlinear kinetics of PHT. The decrease in clearance observed with increasing 
concentrations would be secondary to the induction of drug secretion from the 
blood into the intestine, from where it is subsequently reabsorbed. A concentration-
local induction dependent on the transport of efflux caused by PHT itself would 
enhance the processes that prolong its permanence in the splanchnic zone. This 
would lead to a decrease in the amount of drug metabolized in the liver and a 
greater percentage of it would enter the process of enterohepatic recirculation, 
sending the drug to an area of poor metabolism such as the intestine from which 
it enters the body again. This effect could be responsible for both the low peak-to-
trough fluctuation mentioned earlier and the disproportionate increase in plasma 
concentrations with dose increase.
The most common antiepileptic comedications in the patients included in the 
study were carbamazepine, lamotrigine, levetiracetam, and valproic acid.
Most adverse reactions with both Antepil® and Comitoína® did not deserve 
dose reduction according to the neurologist due to the fact that they were related to 
chronic treatment with PHT. The exception was the appearance of seizures with high 
PHT concentrations, which was considered as a possible concentration-dependent 
adverse reaction. PHT concentrations are responsible for the overexpression of 
9Active Pharmacovigilance in Epileptic Patients: A Deep Insight into Phenytoin Behaviour
DOI: http://dx.doi.org/10.5772/intechopen.80295
efflux transporters, not only in the splanchnic zone but also in the hematoencephalic 
barrier, which could be the reason for low PHT levels in the brain and the appearance 
of seizures.
Some patients taking Antepil® were comedicated with VPA. Ammonia levels 
in some of these patients were higher than the upper limit of the normal range in 
blood (25–94 μg/dL). Our research group has been studying increased ammonia 
levels in patients under VPA treatment [32, 33]. High levels of ammonia in the brain 
can be the cause of seizures as ammonia easily crosses the blood-brain barrier, and 
in the brain, it can conjugate with α-ketoglutarate to form glutamate. This leads 
to brain damage and the appearance of seizures given the excitatory activity of 
glutamate in the synaptic membrane.
Tables 4 and 5 show the detected ADRs in patients under Antepil® or 
Comitoína® treatment, respectively, and the causality assessment using Naranjo’s 
algorithm.
Figure 4. 
Relationship between the normalized dose of PHT and plasma concentration (in red) and salivary 
concentration (in blue) for Comitoína®.
Figure 5. 
Relationship between the normalized dose of PHT and plasma concentration (in red) and salivary 
concentration (in blue) for Antepil®.
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ADRs Causality Total
Possible Probable
Gastrointestinal disorders 2 1 3
Visual problems 3 5 8
Drowsiness 0 7 7
Dizziness 1 5 6
Dysarthria 1 2 3
Bleeding gums/hyperplasia 0 7 7
Memory loss 0 4 4
Walk instability 0 1 1
Tremor in hands 1 0 1
Headaches 0 1 1
Belly swelling 1 0 1
Irritability 0 1 1
Nervousness 0 1 1
Total 9 35 44
Table 5. 
Detected adverse drug reactions (ADRs) and causality assessment in patients under Comitoína® treatment.
ADRs Causality Total
Possible Probable
Gastrointestinal disorders 1 3 4
Visual problems 0 3 3
Drowsiness 3 0 3
Dizziness 2 1 3
Dysarthria 0 3 3
Bleeding gums/hyperplasia 0 1 1
Memory loss 0 1 1
Tremor in hands 0 1 1
Trouble in sleeping 0 2 2
Lack of strength in lower limbs 2 0 2
Orthostatic hypotension 0 1 1
Walk instability 1 1 2
Seizures* 1 3 4
Total 10 20 30
*Seizures were reported as toxic reactions and not treatment failure when plasma levels of PHT were greater than 
20 mg/L and when once the dose was reduced seizures disappear. In one patient, this adverse effect was assessed as 
possible as the patient was comedicated with VPA (1200 mg) and the ammonia level was 165.8 μg/dL, and as it was 
explained previously, VPA provoking hyperammonemia could be the cause of the seizures. Predose plasma levels of 
PHT and VPA were 24.8 and 49.7 mg/L, respectively, in this patient.
Table 4. 
Detected adverse drug reactions (ADRs) and causality assessment in patients under Antepil® treatment.
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None of the patients developed skin reactions, an adverse effect observed in a 
clinical trial with healthy volunteers that was carried out by our research group [13]. 
It deserves to be mentioned that oral chronic administration of PHT induces micro-
somal EPHX, which could explain why the percentage of subjects with toxicity is 
higher at the early stage of the treatment (healthy volunteers) than after a chronic 
one (patients participating in the pharmacovigilance program). A lesser exposure 
of reactive metabolite during chronic administration could be due to enzyme induc-
tion by PHT.
Although the number of ADRs was greater under Comitoína® treatment, the 
severity of such reactions was less intense as no seizures due to high concentrations 
was carried out reported.
One limitation of the study was self-reported data of ADRs when patients 
filled the form. This can inherently bias the number and severity of the reported 
reactions.
For both brands, when seizures and low concentrations were present, lack of 
efficacy was suspected, and then, the dose was immediately increased in order to 
achieve therapeutic concentrations.
Mean dose and mean plasma and salivary concentration of PHT that were able 
to control the seizures for Antepil® and Comitoína are shown in Tables 6 and 7, 
respectively.
As the three main enzymes that participate in PHT metabolism are polymorphi-
cally expressed and the genetic variants are responsible for changes in the enzyme 
activity, our research group has also evaluated the effect that these polymorphisms 
have on PHT metabolism. The genotypic frequencies obtained for CYPs are in 
accordance with the ones reported for Caucasian population [34]. Thirty percent-
age of the patients were intermediate, and 2% were poor metabolizers for CYP2C9, 
whereas 20% were intermediate metabolizers for CYP2C19. No poor metabolizer 
was found for CYP2C19. Regarding EPHX, 44% of the patients had an intermedi-
ate, 10% an increased, and 46% a decreased enzyme activity. Although 46% of the 
patients had a decreased EPHX activity, none of the patients reported cutaneous 
reactions. As it was stated, not only the detoxification pathway but also the rate of 
formation of this toxic metabolite (arene oxide) must be taken into account. Both 
formulations behave as slow-release tablets. Moreover, during chronic admin-
istration, a lesser exposure of reactive metabolite can be experienced due to the 
enzyme induction PHT provokes. Our results also evidenced a predominant role of 
CYP2C9 in PHT biotransformation, while CYP2C19 seems to have a predominant 
role in p-HPPH biotransformation [31].
Dose (mg/kg) [Po] (mg/L) [So] (mg/L)
4.03 (3.77–4.29) 7.12 (5.81–8.44) 0.626 (0.491–0.760)
Table 6. 
Mean (95% CI) PHT dose and mean plasma and salivary concentrations in patients with controlled seizures 
under Antepil® treatment.
Dose (mg/kg) [Po] (mg/L) [So] (mg/L)
4.34 (4.12–4.55) 9.14 (8.08–10.2) 0.930 (0.780–1.08)
Table 7. 
Mean (95% CI) PHT dose and mean plasma and salivary concentrations in patients with controlled seizures 
under Comitoína® treatment.
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A bioequivalence parallel design study in saliva was also carried out with these 
data. According to the results obtained in this study, for the three parameters 
under evaluation (Css, Cmax, and PTF), bioequivalence between Antepil® and 
Comitoína® can be concluded. This procedure of parallel assay, with replicate evalu-
ation of drug exposure, becomes a valuable solution to demonstrate bioequivalence 
of such products [35].
5. Conclusions
Both oral formulation of PHT show a uniform behavior in the population stud-
ied. The dose increase caused a disproportionate increase in plasma concentrations 
(Michaelis-Menten kinetics), as referenced in the literature.
No statistically significant differences were detected between the normalized 
doses received by both sexes or in the salivary concentrations or plasma concentra-
tions obtained with such doses.
The presence of secondary peaks in salivary curves revealed the recirculation 
processes already known for PHT.
Adverse drug reactions referenced by patients did not deserve medical 
intervention in most cases, except for the appearance of seizures with high PHT 
concentrations.
CYP2C9 polymorphisms affect mainly PHT concentrations, while CYP2C19 
polymorphisms affect mainly p-HPPH concentrations, which verify the predomi-
nant role that CYP2C9 has in PHT metabolism and CYP2C19 in p-HPPH metabo-
lism. A decreased EPHX activity did not evidence arene oxide accumulation as no 
cutaneous reactions were observed.
According to the results obtained in the parallel study, switchability between the 
two commercial brands can be inferred.
In summary, mean (95% CI) PHT dose of 4.34 (4.12–4.55) mg/kg of Comitoína® 
and 4.03 (3.77–4.29) mg/kg of Antepil® achieved effective and safe concentrations 
of PHT.
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